CJC-1295 research guide for Oxinam. Covers DAC vs no-DAC forms, half-life differences, purity testing, and how to source quality CJC-1295 for research.
Most researchers trying to source CJC-1295 in Oxinam rapidly learn that local retail options are virtually absent. What this means for Oxinam researchers is that your location matters far less than your ability to verify analytical documentation — and those verification methods are within reach of all serious researchers. What genuinely separates top CJC-1295 vendors is full COA coverage: HPLC for purity, mass spec for molecular identity verification, and endotoxin testing for contamination assurance. This guide gives Oxinam researchers the practical tools to evaluate CJC-1295 vendors systematically and source high-purity CJC-1295 with confidence.
What Studies Say About CJC-1295
The selectivity profile of different GHS compounds is a critical research consideration. GHRP-6 and GHRP-2 produce GH release alongside cortisol and prolactin elevation — a confounding factor in research designs where these hormones are outcome variables. Ipamorelin was specifically developed for greater GH-release selectivity with minimal cortisol and prolactin elevation, making it more suitable for research designs where GH-specific effects need to be isolated. Hexarelin has the strongest GH-releasing potency in the GHRP class but also the most significant cortisol and prolactin effects. For Oxinam researchers designing GH-axis studies, compound selection based on this selectivity profile should precede protocol finalization.
How to Source CJC-1295 — Vendor Guide
Before looking at individual vendors, establish a quality benchmark — so you can tell whether a COA is complete and credible. A COA for CJC-1295 should include: HPLC purity percentage with the full chromatographic trace, mass spectrometry data establishing the correct molecular weight, endotoxin test results, and a residual solvent panel — all traceable to your batch. Negative indicators in CJC-1295 vendor evaluation: prices significantly below market average, unclear production details, no community presence, and COAs that do not include endotoxin results. Price is an poor proxy for CJC-1295 quality — research-grade synthesis and testing has unavoidable expenses that low-priced vendors are not absorbing, so significantly below-market pricing signals compromises.
Order CJC-1295 — ships to Oxinam
COA-verified · International tracking · Research grade
As a research compound, CJC-1295 has not been through the clinical trial process required for pharmaceutical approval — its safety profile is characterised by preclinical data and small-scale human observations. Reconstitute CJC-1295 with bacteriostatic water at a concentration matched to your dosing requirements; a standard 5mg in 2mL gives a 2.5mg/mL solution — or 25mcg per insulin syringe unit. The primary quality-related safety risk in CJC-1295 research is endotoxin from inadequately tested product — a confirmed endotoxin test result in the lot-matched COA is the key safeguard. Protocol documentation — keeping clear records of compound, timing, and method — is a sound practice for any CJC-1295 protocol that makes anomalous results interpretable.
Frequently Asked Questions
What is the difference between CJC-1295 with DAC and without DAC?
CJC-1295 with DAC uses a lysine-maleimide conjugate to bind covalently to albumin in the bloodstream, extending half-life to ~6-8 days and creating sustained GH elevation. CJC-1295 without DAC (also called Mod GRF 1-29) has a half-life of ~30 minutes and produces acute GH pulses. They produce different GH secretion patterns and have different applications in research.
What purity is required for CJC-1295 research?
CJC-1295 should be ≥98% pure by HPLC. The larger molecular weight of CJC-1295 with DAC (approximately 3647 Da) makes mass spectrometry confirmation particularly important, as impurities may not be obvious on HPLC alone.
What is CJC-1295?
CJC-1295 is a synthetic GHRH (Growth Hormone Releasing Hormone) analogue. The version with DAC (Drug Affinity Complex) has an extended half-life of approximately 6-8 days due to albumin binding. Without DAC, CJC-1295 has a much shorter half-life similar to native GHRH. Both versions stimulate pulsatile GH release via the GHRH receptor.
